Larimar Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.83 Insider Own7.80% Shs Outstand43.27M Perf Week-0.32%
Market Cap134.11M Forward P/E- EPS next Y-1.60 Insider Trans347.16% Shs Float39.71M Perf Month2.27%
Income-35.10M PEG- EPS next Q-0.48 Inst Own90.90% Short Float / Ratio0.83% / 1.90 Perf Quarter14.49%
Sales- P/S- EPS this Y17.50% Inst Trans170.65% Short Interest0.33M Perf Half Y21.07%
Book/sh5.34 P/B0.59 EPS next Y34.30% ROA-40.60% Target Price12.67 Perf Year-67.01%
Cash/sh2.94 P/C1.08 EPS next 5Y- ROE-48.30% 52W Range1.53 - 11.31 Perf YTD-70.71%
Dividend- P/FCF- EPS past 5Y35.00% ROI- 52W High-72.06% Beta0.75
Dividend %- Quick Ratio13.50 Sales past 5Y- Gross Margin- 52W Low106.54% ATR0.20
Employees31 Current Ratio13.50 Sales Q/Q- Oper. Margin- RSI (14)53.90 Volatility8.11% 6.77%
OptionableYes Debt/Eq0.00 EPS Q/Q59.30% Profit Margin- Rel Volume0.32 Prev Close3.17
ShortableYes LT Debt/Eq0.00 EarningsNov 10 BMO Payout- Avg Volume174.02K Price3.16
Recom1.50 SMA203.96% SMA500.83% SMA2004.95% Volume56,213 Change-0.32%
Oct-19-22Initiated Guggenheim Buy $12
Feb-15-22Downgrade William Blair Outperform → Mkt Perform
Feb-10-21Initiated JMP Securities Mkt Outperform
Feb-01-21Initiated William Blair Outperform $29
Nov-21-22 04:05PM
Nov-10-22 07:00AM
Nov-07-22 04:05PM
Oct-20-22 08:00AM
Oct-19-22 04:05PM
01:00PM Loading…
Sep-16-22 01:00PM
Sep-14-22 07:04AM
Aug-11-22 04:05PM
Jul-28-22 04:05PM
Jun-28-22 08:00AM
Jun-02-22 08:00AM
May-19-22 08:00AM
May-12-22 07:00AM
06:27AM Loading…
Apr-29-22 06:27AM
Apr-13-22 10:40AM
Mar-25-22 07:00AM
Feb-16-22 11:57AM
Feb-14-22 04:01PM
Jan-19-22 06:53AM
Nov-22-21 07:00AM
Nov-20-21 08:40AM
Nov-15-21 07:00AM
Nov-12-21 07:00AM
Sep-16-21 08:00AM
Sep-02-21 04:01PM
Aug-22-21 10:12AM
Aug-19-21 07:00AM
Aug-12-21 07:00AM
08:48AM Loading…
Aug-09-21 08:48AM
Jul-23-21 12:00PM
Jul-08-21 04:01PM
Jun-11-21 07:00AM
Jun-05-21 07:55PM
Jun-02-21 10:56PM
Jun-01-21 04:55AM
May-29-21 10:59PM
May-25-21 05:41PM
May-21-21 09:18AM
May-20-21 04:31PM
May-11-21 07:00AM
May-10-21 04:05PM
Mar-04-21 07:00AM
Mar-01-21 03:54AM
Feb-18-21 04:01PM
Dec-16-20 07:23PM
Dec-15-20 08:00AM
Dec-08-20 07:30AM
Nov-13-20 08:00AM
Nov-10-20 08:00AM
Oct-14-20 10:18PM
Oct-13-20 08:00AM
Sep-21-20 09:58AM
Sep-10-20 08:00AM
Sep-01-20 12:47PM
Aug-11-20 07:00AM
Aug-04-20 08:00AM
Jul-28-20 08:00AM
Jul-20-20 04:15PM
May-29-20 04:05PM
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BEN-MAIMON CAROLEPresident and CEOSep 16Buy3.1531,746100,00056,829Sep 19 07:00 AM
Celano MichaelChief Financial OfficerSep 16Buy3.1531,746100,00031,746Sep 19 07:00 AM
Flynn James EDirectorSep 16Buy3.1511,111,10834,999,9904,721,200Sep 20 08:31 PM
Hamilton Thomas EdwardDirectorSep 16Buy3.15317,460999,999507,590Sep 20 06:54 AM